Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04133311
Other study ID # 0130A01SA
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date April 10, 2019
Est. completion date October 26, 2022

Study information

Verified date May 2024
Source Santen SAS
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase III, Multinational, Multicenter, Investigator-Masked, Randomized, Active-Controlled Trial, comparing the efficacy and safety of DE-130A with Xalatan® in Patients with Open-Angle Glaucoma or Ocular Hypertension over a 3-Month period, followed by a 12-Month Follow-Up with Open-Label DE-130A Treatment.


Description:

Phase III, prospective, interventional, multinational, multicentre, investigator-masked, randomized, active-controlled trial Study duration: - 5 days to 5-week washout period - 15 months for the first 130 patients - 12 weeks for the next 250 patients Patients will attend 6 visits following the wash-out phase (up to 5 weeks): - Period 1 (3-month investigator-masked treatment period, DE-130A vs Xalatan®): Randomization/Baseline visit (Day 1), Week 4 (±3 days) and Week 12 (±3 days) - Period 2 (12-month follow-up from Week 12, open-label DE-130A treatment for the first 130 patients who complete their week 12 visit and agree to participate in the open-label period of the study): Month 6 (± 7days), Month 9 (±7 days) and Month 15 (± 1 week) visits.


Recruitment information / eligibility

Status Completed
Enrollment 386
Est. completion date October 26, 2022
Est. primary completion date February 3, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female, 18 years of age or older 2. The patient has signed and dated a written informed consent form and any required privacy authorization prior to the conduct of any study procedures. 3. Diagnosis of OAG (primary open angle glaucoma, pseudo exfoliative glaucoma, or pigmentary glaucoma), or OHT in eligible eye(s) currently on monotherapy. 4. Unilateral OAG, or OHT are permissible as long as the physician does not anticipate significant IOP changes to the fellow eye that would require treatment during the duration of the study. 5. Current treatment with monotherapy for OAG or OHT with a controlled IOP = 18 mmHg in each eye (pre-washout). 6. Stable visual field (based on at least two visual fields available within the last 18 months prior to screening, including one in the last 6 months; A visual field test will be performed at screening if not already performed within the last 6 months prior to screening) in each eye. 7. Post-washout IOP = 22 mmHg in at least one eye (defined at baseline visit [Day 1] by IOP measurement at both 9:00 am ± 1 hour and 4:00 pm ±1 hour) 8. Post-washout IOP = 32 mmHg (defined at baseline visit [Day 1] by IOP measurement at both 9:00 am ±1 hour and 4:00 pm ±1 hour) in both eyes. 9. Ability to discontinue their current topical IOP-lowering medication for the required washout period. Washout periods should be as follows; - Prostaglandin analogs = 4 weeks - Topical beta blockers = 3 weeks and = 4 weeks - Topical carbonic anhydrase inhibitors = 5 days and = 4 weeks - All other IOP lowering medication = 2 weeks and = 4 weeks 10. Snellen best corrected visual acuity score of 20/100 or better in each eye 11. Patient must be willing to discontinue wearing contact lenses during the study. 12. Adequate health for study participation as determined by the investigator 13. In the opinion of the investigator, the patient is capable of understanding and complying with protocol requirements 14. Patient must be willing and able to undergo and return for scheduled study-related examinations. - Exclusion Criteria: 1. Any form of glaucoma other than primary open angle glaucoma, pseudo exfoliative glaucoma, and pigmentary glaucoma in either eye. 2. IOP at any time point during the Screening or Baseline visits (Visits 1 or 2) of > 32 mmHg in either eye. 3. Current treatment for glaucoma with a fixed-combination therapy or more than one drug in either eye or with an oral drug within 6 months prior to screening. 4. Corneal abnormalities that would interfere with accurate IOP readings with an applanation tonometer in either eye. 5. Central corneal thickness = 480 µm or = 600 µm in either eye (historical data or at the screening visit). 6. Significant visual field loss (absolute defect in the 10° central point or mean deviation worse than -12 dB) or progressive field loss during the year before screening in either. 7. Significant optic nerve abnormality, other than glaucomatous abnormalities in the opinion of the investigator as determined by ophthalmoscopy in either eye. 8. Significant changes of the optic neuropathy (e.g. increase cupping since the last examination, optic nerve hemorrhage) in either eye. 9. Inability to visualize the patient's optic nerve in either eye. 10. Gonioscopy consistent with potential angle closure glaucoma in either eye. 11. Patients with severe blepharitis and/or Meibomian Gland Disease (MGD). Patients enrolled with mild to moderate blepharitis and/or MGD should be treated as appropriate during the study in either eye. 12. Use of oral or topical ophthalmic steroid within the past 14 days from screening date, or anticipated need for ocular steroid treatment during the study in either eye. 13. Use of intravitreal or peribulbar injection of depot steroid or placement of an intravitreal steroid implant within the past 3 months from screening date in either eye. 14. Known allergy or sensitivity to the study medications. 15. Active or expected ocular allergy during period 1. 16. Any active ocular disease (e.g. uveitis, ocular infection, severe dry eye with CFS grade 4 or more on the modified Oxford scale) in either eye. Patients may have mild cataracts, age-related maculopathy or background diabetic retinopathy if, in the opinion of the Investigator, it would not interfere with the conduct of the study. 17. Intraocular surgery within 6 months prior to screening in either eye. 18. Past history of any filtering surgery for glaucoma in either eye. 19. Refractive surgery of any type within 1 year prior to screening in either eye. 20. Uncontrolled systemic disease of any type. 21. Anticipated alteration in chronic therapy with or introduction of agents known to have a substantial effect on IOP (e.g., alpha-adrenergic agonists, beta-adrenergic antagonists, calcium channel blockers, ACE inhibitors and/or angiotensin II receptor blockers), unless the subject and the medication dosage have been stable for three months prior to the screening visit and the dosage is not expected to change during the study. 22. Anticipated change in dosage of or introduction of new medications for chronic cardiac, pulmonary or hypertensive conditions. 23. Females who are pregnant or lactating and females of child-bearing potential who are not using a medically acceptable, highly effective method of birth control. 24. Current enrolment in an investigational drug or device study or participation in such a study within 30 days prior to screening. 25. History of drug or alcohol abuse. 26. Patient has any condition or situation that, in the Investigator's opinion, might confound the results of the study, may put the patient at significant risk or might interfere with the patient's ability to participate in the study. -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
DE-130A
Latanoprost 50 microg/ml eye drops emulsion, preservative-free eye drops emulsion in single-dose containers.
Xalatan®
Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers.
DE-130A/DE-130A
After Week 12, received DE-130A continuously.
Xalatan®/DE-130A
From week 12 onwards, DE-130A was continued to be administered instead of Xalatan®.

Locations

Country Name City State
France Hôpital des XV-XX Paris Île-de-France

Sponsors (1)

Lead Sponsor Collaborator
Santen SAS

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intraocular Pressure (IOP) Change (mmHg) at Week 12 Intraocular Pressure (IOP) change from baseline peak (mmHg). IOP was measured using calibrated Goldman applanation tonometer in the morning (9:00 am ± 1 hour). Analysis using Mixed-Effects Model for Repeated Measures (MMRM). Week 12 (09:00) peak timepoint
Primary Intraocular Pressure (IOP) Change (mmHg) at Week 12 Intraocular Pressure (IOP) change from baseline trough (mmHg). IOP was measured using calibrated Goldman applanation tonometer in the afternoon (4:00 pm ± 1 hour). Analysis using Mixed-Effects Model for Repeated Measures (MMRM). Week 12 (16:00) trough timepoint
Secondary Corneal Fluorescein Staining (CFS) Change From Baseline (First Key Secondary Endpoint) CFS Change from baseline in participants with baseline CFS score = 1 at Week 12
Staining using fluorescein were graded using the Modified Oxford scale (7-point ordinal scale, score 0, 0.5, and 1 to 5 per area for cornea and conjunctiva separately) as shown below:
Score = 0: No staining dots
Score = 0.5: One staining dot per area
Score = 1: More staining dot per area than score 0.5
Score = 2: More staining dot per area than score 1
Score = 3: More staining dot per area than score 2
Score = 4: More staining dot per area than score 3
Score = 5: More staining dot per area than score 4
A Mixed-Effects Model for Repeated Measures (MMRM) was fitted to the CFS change from baseline at each visit.
Week 12
Secondary Ocular Surface Disease (OSD) Symptoms (Average of 3 Symptoms); Second Key Secondary Endpoint Change from baseline in OSD symptom score (average of 3 symptoms: dry eye sensation, blurred/poor vision and burning/stinging/itching) in the study eye at Week 12 in patients with baseline symptom average score>0.
Ocular symptoms were graded on a 5-point scale as shown below:
Scale = 0: Absent
Scale = 1: Mild
Scale = 2: Moderate
Scale = 3: Severe
Scale = 4: Very severe
Least Square Means and p-values were obtained by fitting a Mixed-Effects Model for Repeated Measures (MMRM) model to the Ocular Surface Disease (OSD) average change from baseline at each visit.
Week 12
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04067973 - Impact of Prematurity on the Optic Nerve
Completed NCT04828057 - Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Not yet recruiting NCT06375343 - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® Phase 1
Completed NCT00346450 - Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Phase 3
Completed NCT04351100 - Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients
Completed NCT03659955 - Autologous Blood Treatment for Ocular Surface Disease N/A
Completed NCT04536129 - Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure N/A
Completed NCT01254370 - Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease Phase 2
Completed NCT00554411 - Assessing Ocular Surface Changes After Changing Glaucoma Medications N/A
Completed NCT03769454 - A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers Phase 1
Recruiting NCT06256770 - Evaluation of the Safety and Efficacy of Rigid Breathable Scleral Contact Lenses for the Correction of Ametropia
Completed NCT04673604 - From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy N/A
Not yet recruiting NCT06370585 - Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF Phase 1
Withdrawn NCT04735510 - Novel Use of Restasis and PROSE Devices Phase 3
Suspended NCT00348114 - Transplantation of Cultivated Limbal Epithelium on Amniotic Membrane for Limbal Stem Cell Deficiency Phase 2
Recruiting NCT04010422 - Ocular Function in Autism Spectrum Disorder
Completed NCT05528016 - Short and Long-term Results of Skin Versus Skin Plus Orbicularis Resection Blepharoplasty N/A
Completed NCT04452279 - Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification N/A
Completed NCT04535388 - LK Scleral Lens for Patients With Intractable Ocular Surface Diseases N/A
Recruiting NCT06298890 - The Pattern of Dry Eye Disease After Cataract Surgery